SLU-PP-332
The recent FDA regulations have impacted the availability of certain substances essential for peptide production by compounding pharmacies. Despite these changes, we are pleased to announce that specific peptides remain available through our services, contingent upon a medical consultation. We appreciate your ongoing support as we adapt to these regulatory adjustments. To discuss your options and continue benefiting from our peptide offerings, please book a consultation with us today.
Semaglutide and Tirzepatide are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). I hereby declare that I do not have a personal or family history of MTC or MEN 2.
Description
SLU-PP-332 is a pan-estrogen-related receptor (ERRα/β/γ) agonist under investigation as an “exercise-mimetic” metabolic modulator. In animal and cell studies, it has been shown to enhance mitochondrial function, increase oxidative metabolism, and improve markers tied to metabolic syndrome, endurance, and age-related mitochondrial decline.
Mechanism of Action
By agonizing ERRs – key nuclear receptors that cooperate with PGC-1α – SLU-PP-332 drives transcription of genes for mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation, and glucose handling. Reported EC₅₀ values are in the sub-micromolar range (most potent at ERRα), aligning with observed gains in cellular respiration and exercise-like metabolic programs in preclinical models.
Related peptides
Frequently Asked Questions
Peptides are short chains of amino acids that perform various bodily functions, such as stimulating growth, tissue regeneration, or enhancing cognitive functions.
Peptides activate specific receptors or biochemical pathways in the body, leading to the desired therapeutic effects.
Depending on the type of peptide, benefits include improved sexual function, muscle growth, reduced inflammation, enhanced cognitive functions, and more.
Results can be seen within a few weeks after starting the therapy, although this can vary based on individual patient characteristics and the specific peptide.
Possible side effects include mild irritation at the injection site, headaches, nausea, and others, depending on the specific peptide.
The recommended frequency of use depends on the specific peptide and can range from daily use to several times a week. Your doctor will provide specific recommendations.
Peptides are not recommended for individuals with certain medical conditions, pregnant or breastfeeding women. Always consult with your doctor before starting the therapy.